-+ 0.00%
-+ 0.00%
-+ 0.00%
Evotec, Bristol Myers Squibb Secure Second US FDA Approval for Drug Candidate
Share
Listen to the news
02:15 AM EST, 11/19/2026 (MT Newswires) -- German life science company Evotec (EVT.F) and Bristol Myers Squibb obtained a second investigational new drug clearance from the US Food and Drug Administration under their strategic protein degradation partnership. The newly cleared drug candidate, a cereblon E3 ligase modulator, is expected to enter a phase 1 clinical trial in 2027, according to a Thursday release. The companies' first candidate under the partnership began phase 1 trials for advanced clear cell renal cell carcinoma in March.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending